Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Remarkable progress has been made in the field of cancer immunotherapy in the past few years. Immunotherapy has become a standard treatment option for patients with various cancers, including melanoma, lymphoma, and carcinomas of the lungs, kidneys, bladder, and head and neck. Promising immunotherap...
Main Authors: | Jun Zhang, L. Jeffrey Medeiros, Ken H. Young |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00351/full |
Similar Items
-
Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
by: Chunmeng Wang, et al.
Published: (2021-07-01) -
Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01) -
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01) -
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01) -
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
by: Cai J, et al.
Published: (2019-10-01)